Blood Sugar, Insulin, and Cancer Risk

Insulin is a growth-signaling hormone as well as a blood sugar regulator. Insulin resistance and chronic hyperinsulinemia have been studied in relation to obesity, diabetes, inflammation, and cancer risk. This does not mean sugar directly “feeds cancer” in a simplistic way, but metabolic health is part of the broader cancer terrain (Szablewski, Current Oncology, 2024).

Every cell uses glucose, including healthy brain and immune cells. The goal is not fear-based restriction. The goal is stable energy, adequate nourishment, muscle preservation, and metabolic flexibility when clinically appropriate.

A supportive plan often emphasizes protein at meals, fiber-rich carbohydrates when tolerated, healthy fats, resistance training, walking after meals when safe, sleep, and medication review. For patients losing weight or struggling to eat during treatment, adequate calories may be more important than glucose optimization (Ligibel et al., ASCO Guideline on Exercise, Diet, and Weight Management During Cancer Treatment, 2022).

Patients with cachexia, poor appetite, nausea, steroids, diabetes medications, pancreatic cancer, tube feeding, or advanced disease need individualized nutrition and medical guidance.

SANAVITA Health provides physician-led integrative oncology education and support with a focus on clarity, safety, whole-person care, and collaboration. The goal is to help patients understand their options, reduce avoidable risk, and build a supportive plan that fits their diagnosis, treatment phase, values, and care team recommendations.